On June 30, 2017, Zhang, Yinsheng; Gao, Yong; Ren, Jing; Wang, Qinglin; Wang, Zhao published a patent.Related Products of 16230-24-3 The title of the patent was 2,4-Disubstituted pyrimidine compounds as EGFR or/and ALK inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:
The invention relates to 2,4-disubstituted pyrimidine compounds of formula I, pharmaceutically acceptable salts, pharmaceutical compositions, and application thereof in treating diseases induced by EGFR or/and ALK. Compounds of formula I wherein X and Y are independently N and CH; R1 is H, halo, CF3, CN; R2 and R6 are independently H, C1-6 alkoxy; R3 and R5 are independently H, acroylamino; R4 is (un)substituted 3- to 8-membered heterocyclic ring, -Z-(CH2)1-4-NR9R10; R7 is H, C1-6 alkoxy, -Z-(CH2)1-4-NR9R10, (un)substituted piperazinyl; R9 and R10 are independently H and C1-4 alkyl; Z is O, S, NH and derivatives; and their pharmaceutically acceptable salts as EGFR or/and ALK inhibitors in the treatment of diseases thereof, are claimed. Compounds of formula I were prepared by using condensation and reduction as the key steps. All the invention compounds were evaluated for their EGFR or/and ALK inhibitory activity. The experimental process involved the reaction of N-(3-Aminophenyl)acrylamide(cas: 16230-24-3).Related Products of 16230-24-3
The Article related to pyrimidine preparation egfr alk inhibitor treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Pyrazines and Quinoxalines (Including Piperazines) and other aspects.Related Products of 16230-24-3
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics